revolade
novartis europharm limited - eltrombopag - purpura, trombosytopeeninen, idiopaattinen - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ja 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ja 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.
febrivac 3-plus injektioneste, suspensio
idt biologika gmbh - clostridium botulinum type c toxoid, pseudomonas aeruginosa bacteria, serotypes 7-8, inactivated, mink parvovirus, type 1, inactivated, pseudomonas aeruginosa bacteria, serotype 6, inactivated, pseudomonas aeruginosa -bacteria, serotype 5, inactivated - injektioneste, suspensio - minkin enteriittivirus - / parvovirus - + inaktivoitu klostridirokote + inaktivoitu pseudomonas -rok
avipro gumboro vac kylmäkuivattu kuiva-aine suspensiota varten
lohmann animal health gmbh - gumborotautivirus, elävä kylmäkuivattu - kylmäkuivattu kuiva-aine suspensiota varten - gumboron tauti -rokote
hipracox broilers oraalisuspensio
laboratorios hipra s.a. - eimeria acervulina hp ookysta, elävä heikennetty,eimeria mitis hp ookysta, elävä heikennetty,eimeria maxima cp ookysta, elävä heikennetty,eimeria tenella hp ookysta, elävä heikennetty,eimeria praecox hp ookysta, elävä heikennetty - oraalisuspensio - kokkidirokote
suvaxyn m.hyo-parasuis injektioneste, suspensio
zoetis finland oy - haemophilus parasuis -bakteereja, inaktivoituja, serovariantti 5,haemophilus parasuis -bakteereja, inaktivoituja, serovariantti 4,mycoplasma hyopneumoniae, j kanta inaktivoitu - injektioneste, suspensio
trilyme injektioneste, suspensio
boehringer ingelheim animal health nordics a/s - borrelia afzelii,borrelia burgdorferi sensu stricto,borrelia garinii - injektioneste, suspensio
feiba 25 u/ml infuusiokuiva-aine ja liuotin, liuosta varten
baxalta innovations gmbh - tekijä viii: n estäjä ohittaen toimintaa - infuusiokuiva-aine ja liuotin, liuosta varten - 25 u/ml - hyytymistekijä viii:n vasta-aineen ohittava aine
feiba 50 u/ml infuusiokuiva-aine ja liuotin, liuosta varten
baxalta innovations gmbh - tekijä viii: n estäjä ohittaen toimintaa - infuusiokuiva-aine ja liuotin, liuosta varten - 50 u/ml - hyytymistekijä viii:n vasta-aineen ohittava aine
tecentriq
roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastiset aineet - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq monoterapiana on tarkoitettu aikuisille potilaille, joilla on paikallisesti pitkälle edennyt tai metastaattinen ei-pienisoluinen keuhkosyöpä aikaisemman kemoterapian jälkeen. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq monoterapiana on tarkoitettu aikuisille potilaille, joilla on paikallisesti pitkälle edennyt tai metastaattinen ei-pienisoluinen keuhkosyöpä aikaisemman kemoterapian jälkeen. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
tecvayli
janssen-cilag international n.v. - teclistamab - multiple myeloma - antineoplastiset aineet - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.